Gilead Sciences Inc. ($GILD) Stock Forecast: Up 7.1% Today

What is Gilead Sciences Inc.?

Gilead Sciences is a biopharmaceutical company known for its innovative treatments in HIV, hepatitis, and other infectious diseases. The company has been a key player in the biotech industry for several years.

Why is Gilead Sciences Inc. going up?

GILD stock is up 7.1% on Feb 12, 2025 20:41

• Gilead Sciences experienced a strong bullish movement today following the release of its Q4 financial results and optimistic outlook for 2025.
• The company reported a 6% increase in Q4 revenue, surpassing analyst expectations, and raised its dividend, signaling financial strength and confidence in future performance.
• The market reacted positively to Gilead's announcement of launching Lenacapavir for HIV prevention, indicating potential growth opportunities in its product pipeline.
• Overall, Gilead's solid financial performance and strategic developments have instilled investor confidence, driving the stock price higher in today's trading session.

GILD Price Chart

GILD Technical Analysis

GILD News

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention - Gilead Sciences ( NASDAQ:GILD )

Gilead's Q4 revenue rose 6% to $7.57 billion, surpassing the $7.14 billion consensus. Gilead raised its dividend by 2.6% to $0.79 per share. Get real-time earnings alerts before the market moves and access expert analysis that uncovers hidden opportunities in the post-earnings chaos.

https://www.benzinga.com/general/biotech/25/02/43673047/gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Angi ( NASDAQ:ANGI )

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of Gilead Sciences, Inc. GILD rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above ...

https://www.benzinga.com/25/02/43662093/gilead-sciences-upstart-mercury-general-confluent-and-other-big-stocks-moving-higher-on-wednesday

Coca-Cola, Marriott International And 3 Stocks To Watch Heading Into Tuesday - Astera Labs ( NASDAQ:ALAB ) , Gilead Sciences ( NASDAQ:GILD )

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects The Coca-Cola Co. KO to report quarterly earnings at 52 cents per share on revenue of $10.68 billion before the opening bell, according to data ...

https://www.benzinga.com/news/earnings/25/02/43615521/coca-cola-marriott-international-and-3-stocks-to-watch-heading-into-tuesday

What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday? - Gilead Sciences ( NASDAQ:GILD )

Gilead to report Q4 earnings on Feb. 11, with analysts expecting $1.70 EPS and $7.14B in revenue. Gilead's deal with LEO Pharma includes a $250M upfront payment and up to $1.7B in milestones, impacting 2025 EPS by $0.15-$0.17. Brand New Membership Level: Benzinga Trade Alerts

https://www.benzinga.com/general/biotech/25/02/43604305/what-to-expect-when-biotech-giant-gilead-reports-q4-earnings-on-tuesday

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

https://www.zacks.com/stock/news/2413121/will-these-5-biotech-bigwig-stocks-surpass-q4-earnings-forecast

Trending Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 5.0% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 5.6% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Up 32.5% Today

Zillow Group Inc. ($Z) Stock Forecast: Down 8.4% Today

CVS Health Corporation ($CVS) Stock Forecast: Up 17.4% Today

Gilead Sciences Inc. ($GILD) Stock Forecast: Up 7.1% Today

PancakeSwap ($CAKE) Crypto Forecast: Up 37.3% Today

Jito ($JTO) Crypto Forecast: Up 9.9% Today

Jupiter ($JUP) Crypto Forecast: Up 5.1% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 5.1% Today

Gilead Sciences Inc. Price History

21.05.2024 - GILD Stock was up 9.1%

• Gilead Sciences (GILD) witnessed a notable bullish surge, with shares climbing by 8.5% during the previous trading session.
• The positive market sentiment towards the company may have driven the bullish trend, potentially due to robust financial performance or promising advancements in its pipeline.
• Amid a backdrop of falling futures and a diminishing tech rally preceding a substantial $5 trillion options expiration, investors may have redirected their focus towards more stable sectors like healthcare, benefiting Gilead Sciences.
• The mention of Gilead's significant increase in share price intensified investor interest and positive momentum in the stock, contributing to its bullish trajectory.

07.10.2024 - GILD Stock was up 6.5%

• Gilead Sciences has consistently outperformed the market over the past 20 years, showcasing strong growth and investor confidence.
• The upcoming Q3 earnings report has likely sparked investor optimism, especially regarding the performance of GILD's HIV franchise and oncology sales.
• Despite a slight market dip, Gilead Sciences managed to gain, indicating resilience and potential positive news or market sentiment surrounding the company.

12.01.2025 - GILD Stock was up 8.0%

• Gilead Sciences reported Q4 earnings, with analysts expecting $1.70 EPS and $7.14B in revenue, potentially exceeding forecasts and boosting investor confidence.
• The company's deal with LEO Pharma, including significant upfront payments and future milestones, may have positively influenced market sentiment towards Gilead.
• Despite some bearish options trading activity, the overall positive outlook on GILD's earnings and performance in key therapeutic areas like HIV and oncology likely contributed to the bullish movement.
• Investors are closely watching Gilead's HIV franchise performance and oncology sales, indicating a strong interest in the company's core revenue-generating segments.

23.00.2024 - GILD Stock was down 10.2%

• The bearish movement in GILD can be attributed to the news that Gilead's trial of Trodelvy for metastatic non-small cell lung cancer (NSCLC) failed to meet the primary endpoint. This disappointing result in a late-stage trial for a potential treatment for NSCLC, a common type of lung cancer, has led to a significant drop in Gilead's stock price. The market reacted negatively to this news, causing GILD to plunge more than 10%.

25.03.2024 - GILD Stock was down 1.3%

• Gilead Sciences (GILD) had a bearish movement despite the broader market indices like S&P and NASDAQ closing higher for the third consecutive day.
• The bearish trend in GILD could be attributed to the implied earnings moves today, possibly indicating lower-than-expected results.
• While the overall market was up due to lower yields and a softer economic outlook, GILD might have faced specific challenges or concerns related to its earnings performance.
• The undervalued icons mentioning reliable companies trading at discounts could reflect a sentiment that GILD might be struggling to keep up with market expectations despite its established presence in the pharmaceutical industry.

20.05.2024 - GILD Stock was up 2.7%

• Gilead Sciences saw a significant surge in its stock price following positive data on its HIV prevention drug, lenacapavir, demonstrating 100% efficacy in a Phase 3 trial.
• The Outperform rating on the stock was maintained due to the promising results of the drug, further boosting investor confidence in the company's future prospects.
• This positive news overshadowed other market movements, with Gilead Sciences standing out among the stocks making the biggest moves midday.
• The market's reaction indicates that investors are optimistic about Gilead's potential in the HIV prevention space, driving the stock higher on Thursday.

20.05.2024 - GILD Stock was up 2.2%

• Gilead Sciences experienced a bullish movement today despite the broader market showing gains.
• The celebration of Pride Month by Gilead and Kite Pharma could have boosted investor sentiment and highlighted the company's commitment to diversity and inclusion.
• The positive outlook for biotech stocks, as highlighted by the potential growth of the global biotech industry, may have contributed to increased interest in Gilead Sciences.
• Despite facing challenges with its blood cancer drug Magrolimab, the overall resilience and diversified portfolio of Gilead Sciences could have reassured investors, leading to the bullish market movement.

20.05.2024 - GILD Stock was up 5.1%

• Gilead Sciences stock surged after the company shared positive results from its Phase 3 trial on the effectiveness of its HIV prevention drug, lenacapavir, showcasing 100% efficacy in cisgender women.
• The upbeat earnings report from KB Home and other big stocks moving higher on Thursday might have contributed to overall positive market sentiment, boosting Gilead's stock as well.
• Gilead's long-term outperformance in the market, with a 20-year investment yielding significant returns, could have also attracted investors to the stock.
• The company's celebration of Pride Month with Kite Pharma, showing support for LGBTQ+ communities, might have resonated positively with investors, adding to the bullish momentum of the stock.

25.06.2024 - GILD Stock was up 5.1%

• Gilead Sciences witnessed a strong bullish movement on the market.
• This positive market sentiment stems from the favorable reception of new data on HIV treatments showcased at AIDS 2024. The data revealed significant advancements such as 100% suppression rates in Hispanic patients, the introduction of promising weekly dosing options, and innovative long-acting therapies.
• Additionally, the bullish positioning of high-profile investors in Gilead Sciences, supported by options data available to the public, likely contributed to the upward momentum.
• The recent announcement of a twice-yearly injection providing 100% protection against HIV in women, as emphasized in a recent study, has also added to the positive outlook on Gilead's future prospects within the HIV treatment sector.

25.06.2024 - GILD Stock was up 6.3%

• Gilead Sciences' stock surged today following the groundbreaking results of its lenacapavir HIV prevention trial, showcasing 100% efficacy in protecting against HIV.
• The positive news of the twice-yearly injectable's superior performance compared to daily oral PrEP likely boosted investor confidence in Gilead's innovative pipeline.
• The competition in the HIV treatment space, highlighted by another company matching Gilead's three-drug combo with a two-drug regimen, also underscored the potential for growth and market leadership in this sector.
• Overall, Gilead's advancements in HIV prevention and treatment are driving optimism among investors, propelling the stock to a bullish trajectory.

12.01.2025 - GILD Stock was up 7.5%

• Gilead Sciences experienced a notable increase in its stock price due to the announcement of better-than-expected fourth-quarter financial results and optimistic FY25 adjusted EPS guidance.
• The market responded positively to Gilead's strategic collaborations, including the recent partnership with LEO Pharma involving significant upfront payments and potential milestones.
• Despite prevailing market pessimism and concerns from institutional investors about Gilead Sciences options trading, the company's robust performance and promising future outlook appear to have driven the stock upwards.

12.01.2025 - GILD Stock was up 7.1%

• Gilead Sciences experienced a strong bullish movement today following the release of its Q4 financial results and optimistic outlook for 2025.
• The company reported a 6% increase in Q4 revenue, surpassing analyst expectations, and raised its dividend, signaling financial strength and confidence in future performance.
• The market reacted positively to Gilead's announcement of launching Lenacapavir for HIV prevention, indicating potential growth opportunities in its product pipeline.
• Overall, Gilead's solid financial performance and strategic developments have instilled investor confidence, driving the stock price higher in today's trading session.